RxDoctor Payments Data

Marc Hunt, MD

Internal Medicine · Honolulu, HINPI 1639169378

Payments from drug & device makers

$1,227in general payments, 2019–2025

Across 26 payments — averaging $47.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$317
  • Abiomed$163
  • Shockwave Medical, Inc$138
  • Teleflex LLC$128
  • Edwards Lifesciences$127
  • Bayer$93
  • plus $261 from 6 others

What the payments were for

  • Travel & lodging$403%
  • Food & beverage$1,18797%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,227 in reported general payments places this provider in the 70th percentile of 655 internal medicine providers in Hawaii.

See all internal medicine providers in Hawaii

Medicare billing

Part B allowed, 2024
$118,619
Medicare patients
413
Services billed
1,411

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban66$78,058
EntrestoSacubitril/Valsartan28$48,255
Atorvastatin Calcium62$2,206
Bumetanide16$1,771
Metoprolol Succinate76$1,323
Diltiazem 24hr Er (Cd)Diltiazem Hcl21$1,002
Losartan Potassium54$948
Rosuvastatin Calcium16$691
Amlodipine Besylate59$640
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide16$489
Carvedilol35$458
Amiodarone Hcl19$351
Isosorbide Mononitrate ErIsosorbide Mononitrate15$293
Potassium Chloride14$254
Furosemide40$200

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$63$78,05866 claims
NovartisEntresto$88$48,25528 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 655 internal medicine providers in Hawaii.

Other internal medicine in Honolulu

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →